Search research articles
Contact Us
Filters
Showing results (1-10 of 9) with videos related to
Page
of 1
Sort By:
Acta Medica Academica
|
July 3, 2019
Lung Cancer Genomics
Ankur R Parikh
Seminars in Hematology
|
October 20, 2012
Immunomodulatory treatment of myelodysplastic syndromes: antithymocyte globulin, cyclosporine, and alemtuzumab
Ankur R Parikh, Matthew J Olnes, A John Barrett
Lung Cancer (Auckland, N.Z.)
|
May 31, 2018
Response to rapamycin analogs but not PD-1 inhibitors in PTEN-mutated metastatic non-small-cell lung cancer with high tumor mutational burden
Ankur R Parikh, Siraj M Ali, Alexa B Schrock, et al.
Oncotargets and Therapy
|
December 10, 2015
Incidence and clinical significance of ESR1 mutations in heavily pretreated metastatic breast cancer patients
Jiaxin Niu, Grant Andres, Kim Kramer, et al.
JCO Precision Oncology
|
February 9, 2022
Treatment of Patients With Lobular Breast Cancer Harboring Human Epidermal Growth Factor Receptor 2 Mutation With HER2-Directed Therapy
Dennis L Citrin, Bradford A Tan, Nimesh B Patel, et al.
Blood Advances
|
April 3, 2019
Long-term outcomes in myelodysplastic syndrome patients treated with alemtuzumab
Catherine Lai, Vishal Ranpura, Colin Wu, et al.
Blood
|
December 19, 2013
Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug
Ronan Desmond, Danielle M Townsley, Bogdan Dumitriu, et al.
The New England Journal of Medicine
|
July 6, 2012
Eltrombopag and improved hematopoiesis in refractory aplastic anemia
Matthew J Olnes, Phillip Scheinberg, Katherine R Calvo, et al.
Haematologica
|
December 1, 2020
Eltrombopag monotherapy can improve hematopoiesis in patients with low to intermediate risk-1 myelodysplastic syndrome
Alana Vicente, Bhavisha A Patel, Fernanda Gutierrez-Rodrigues, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 9) with videos related to
Sort By:
Page
of 1
Acta Medica Academica
|
July 3, 2019
Lung Cancer Genomics
Ankur R Parikh
Seminars in Hematology
|
October 20, 2012
Immunomodulatory treatment of myelodysplastic syndromes: antithymocyte globulin, cyclosporine, and alemtuzumab
Ankur R Parikh, Matthew J Olnes, A John Barrett
Lung Cancer (Auckland, N.Z.)
|
May 31, 2018
Response to rapamycin analogs but not PD-1 inhibitors in PTEN-mutated metastatic non-small-cell lung cancer with high tumor mutational burden
Ankur R Parikh, Siraj M Ali, Alexa B Schrock, et al.
Oncotargets and Therapy
|
December 10, 2015
Incidence and clinical significance of ESR1 mutations in heavily pretreated metastatic breast cancer patients
Jiaxin Niu, Grant Andres, Kim Kramer, et al.
JCO Precision Oncology
|
February 9, 2022
Treatment of Patients With Lobular Breast Cancer Harboring Human Epidermal Growth Factor Receptor 2 Mutation With HER2-Directed Therapy
Dennis L Citrin, Bradford A Tan, Nimesh B Patel, et al.
Blood Advances
|
April 3, 2019
Long-term outcomes in myelodysplastic syndrome patients treated with alemtuzumab
Catherine Lai, Vishal Ranpura, Colin Wu, et al.
Blood
|
December 19, 2013
Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug
Ronan Desmond, Danielle M Townsley, Bogdan Dumitriu, et al.
The New England Journal of Medicine
|
July 6, 2012
Eltrombopag and improved hematopoiesis in refractory aplastic anemia
Matthew J Olnes, Phillip Scheinberg, Katherine R Calvo, et al.
Haematologica
|
December 1, 2020
Eltrombopag monotherapy can improve hematopoiesis in patients with low to intermediate risk-1 myelodysplastic syndrome
Alana Vicente, Bhavisha A Patel, Fernanda Gutierrez-Rodrigues, et al.
Page
of 1